Details of the Drug Combinations

General Information of This Drug (ID: DMTD7AB)

Drug Name

Pracinostat DMTD7AB

Synonyms

Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Myelodysplastic syndrome	2A37	Phase 2	[2]
Myelofibrosis	2A20.2	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Pracinostat + Ruxolitinib	DCV52O4	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[3]
Pracinostat + Mitomycin	DCNKF8H	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Pracinostat + Ruxolitinib	DCKZET2	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
------------------------------------------------------------------------------------

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Azacitidine + Pracinostat	DC3B3AG	Azacitidine	Myelodysplastic Syndromes	[5]
Azacitidine + Pracinostat	DCLV1F2	Azacitidine	Myelodysplastic Syndrome	[6]
Ruxolitinib + Pracinostat	DCYFTUF	Ruxolitinib	Myeloproliferative Diseases	[7]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5	ClinicalTrials.gov (NCT03151304) A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
6	ClinicalTrials.gov (NCT01873703) Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
7	ClinicalTrials.gov (NCT02267278) Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)